Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Breast Neoplasms 3Uterine Cervical Neoplasms 1Stomach Neoplasms 1Risk Reduction Behavior 1Patient Preference 1Patient Acceptance of Health Care 1Health Behavior 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Disease 1Behavior 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Carboplatin 71Docetaxel 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Risk Assessment × Clear all
NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting
21,000 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡